ଟାମୋକ୍ସିଫେନ

ଟାମୋକ୍ସିଫେନ
Clinical data
Trade names	Nolvadex, Genox, Tamifen, others
AHFS/Drugs.com	monograph
MedlinePlus	a682414
Pregnancy; category	AU: B3 ; US: D (Evidence of risk) ; ;
Routes of; administration	Oral
ATC code	L02BA01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Protein binding	99%
Metabolism	Hepatic (CYP3A4, 2C9 and 2D6)
Elimination half-life	5-7 days
Excretion	Faeces (65%), urine (9%)
Identifiers
	IUPAC name (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine;
CAS Number	10540-29-1 ;
PubChem CID	2733526;
IUPHAR/BPS	1016;
DrugBank	DB00675 ;
ChemSpider	2015313 ;
UNII	094ZI81Y45;
KEGG	D08559 ;
ChEBI	CHEBI:41774 ;
ChEMBL	CHEMBL83 ;
ECHA InfoCard	100.031.004
Chemical and physical data
Formula	C26H29NO
Molar mass	371.515 g/mol; 563.638 g/mol (citrate salt)
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)CC)CCN(C)C;
	InChI InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- ; Key:NKANXQFJJICGDU-QPLCGJKRSA-N ;
(verify)

ଟାମୋକ୍ସିଫେନ (ଟିଏମଏକ୍ସ), ଯାହାର ଏକ ବିକ୍ରୟ ନାମ ନୋଲଭାଡେକ୍ସ, ଏକ ଔଷଧ ଯାହା ମହିଳାଙ୍କର ସ୍ତନ କର୍କଟର ପ୍ରତିଷେଧକ ଓ ଉଭୟ ମହିଳା ଓ ପୁରୁଷଙ୍କର ସ୍ତନ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ବ୍ୟବ‌ହାର କରାଯାଏ ।^[୩] ଅନ୍ୟାନ୍ୟ କର୍କଟ ରୋଗରେ ଏହାର ବ୍ୟବ‌ହାର ନିମନ୍ତେ ଅନୁଶୀଳନ ଚାଲିଛି । ^[୩] ଆଲବ୍ରାଇଟ ସିଣ୍ଡ୍ରୋମରେ ଏହା ବ୍ୟବ‌ହାର କରାଯାଇଛି । ସ୍ତନ କର୍କଟ ରୋଗରେ ଟାମୋକ୍ସିଫେନ ପ୍ରତ୍ୟହ ୫ ବର୍ଷ ପର୍ଯ୍ୟନ୍ତ ପାଟିରେ ଖାଇବାକୁ ଦିଆଯାଏ । ^[୪]

ଜରାୟୁ କର୍କଟ, ସଂଘାତ (stroke), ଦୃଷ୍ଟି ସମସ୍ୟା ଓ ଫୁସଫୁସ ଏମ୍ବୋଲିଜ୍ମ ଇତ୍ୟାଦି ସାଂଘାତିକ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ସଙ୍କଟ ଦେଖାଯାଇପାରେ । ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ଅନିୟମିତ ଋତୁସ୍ରାବ, ଓଜନ ହ୍ରାସ ଓ ଉଷ୍ମାନୁଭୂତି ଇତ୍ୟାଦି ଦେଖାଯାଏ । ଗର୍ଭାବସ୍ଥା ଓ ସ୍ତନ୍ୟପାନ ସମୟରେ ଏହି ଔଷଧ ଦେଲେ ଶିଶୁର ହାନୀ ହୁଏ ।^[୪] ଏହା ଏକ ବରଣାତ୍ମକ ଏସ୍ଟ୍ରୋଜେନ-ରିସେପ୍ଟର ମୋଡ୍ୟୁଲେଟର ଯାହା ସ୍ତନ କୋଷ ବୃଦ୍ଧିର କାରକ ବା ଫ୍ୟାକ୍ଟରମାନଙ୍କୁ କମେଇଦିଏ ଓ କୋଷବୃଦ୍ଧି କମ କରୁଥିବା କାରକମାନଙ୍କୁ ବଢ଼େଇଦିଏ । ^[୪]^[୫] ଏହା ଟ୍ରାଇଫିନାଇଲଏଥିଲିନ ଦଳର ଔଷଧ । ^[୬]

ସନ ୧୯୬୭ରେ ଟାମୋକ୍ସିଫେନ ଆବିଷ୍କୃତ ହେଲା ।^[୭] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୮] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ ଉପଲବ୍‌ଧ ହୁଏ । ^[୪]ଏହାର ଦୈନିକ ହୋଲସେଲ ଖର୍ଚ୍ଚ ପ୍ରାୟ ୦.୦୭ରୁ ୦.୨୩ ଆମେରିକୀୟ ଡଲାର ।^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଦୈନିକ ଖର୍ଚ୍ଚ ୨ ଡଲାର । ^[୪]

ଆଧାର

↑ "NCI Drug Dictionary". Retrieved 28 November 2015.
↑ "Tamoxifen". Drugs.com.
↑ ^୩.୦ ^୩.୧ "Tamoxifen Citrate". NCI. August 26, 2015. Retrieved 28 November 2015.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Tamoxifen Citrate". The American Society of Health-System Pharmacists. Retrieved 27 Nov 2015.
↑ "Selective estrogen receptor modulators". Retrieved 28 November 2015.
↑ Dueñas-Díez, edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, José-Luis (2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg. p. 52. ISBN 9783540347422. {{cite book}}: |first1= has generic name (help)CS1 maint: multiple names: authors list (link)
↑ Jordan VC (Jan 2006). "Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer". British Journal of Pharmacology. 147 Suppl 1 (Suppl 1): S269-76. doi:10.1038/sj.bjp.0706399. PMC 1760730. PMID 16402113.
↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
↑ "Tamoxifen Citrate". International Drug Price Indicator Guide. Archived from the original on 9 January 2016. Retrieved 28 November 2015.

[1] "NCI Drug Dictionary". Retrieved 28 November 2015.

[2] "Tamoxifen". Drugs.com.

[NCI2015-3] ୩.୦ ^୩.୧ "Tamoxifen Citrate". NCI. August 26, 2015. Retrieved 28 November 2015.

[AHFS2015-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Tamoxifen Citrate". The American Society of Health-System Pharmacists. Retrieved 27 Nov 2015.

[5] "Selective estrogen receptor modulators". Retrieved 28 November 2015.

[6] Dueñas-Díez, edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, José-Luis (2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg. p. 52. ISBN 9783540347422. {{cite book}}: |first1= has generic name (help)CS1 maint: multiple names: authors list (link)

[Jordan_2006-7] Jordan VC (Jan 2006). "Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer". British Journal of Pharmacology. 147 Suppl 1 (Suppl 1): S269-76. doi:10.1038/sj.bjp.0706399. PMC 1760730. PMID 16402113.

[8] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[9] "Tamoxifen Citrate". International Drug Price Indicator Guide. Archived from the original on 9 January 2016. Retrieved 28 November 2015.

[୩]

[୪]

[୧]

[୨]

[୫]

[୬]

[୭]

[୮]

[୯]

Clinical data


Trade names	Nolvadex, Genox, Tamifen, others^[୧]
AHFS/Drugs.com	monograph
MedlinePlus	a682414
Pregnancy category	AU: B3 US: D (Evidence of risk)
Routes of administration	Oral
ATC code	L02BA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	99%
Metabolism	Hepatic (CYP3A4, 2C9 and 2D6)
Elimination half-life	5-7 days^[୨]
Excretion	Faeces (65%), urine (9%)
Identifiers
IUPAC name (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
CAS Number	10540-29-1^Y
PubChem CID	2733526
IUPHAR/BPS	1016
DrugBank	DB00675^Y
ChemSpider	2015313^Y
UNII	094ZI81Y45
KEGG	D08559^Y
ChEBI	CHEBI:41774^Y
ChEMBL	CHEMBL83^Y
ECHA InfoCard	100.031.004
Chemical and physical data
Formula	C₂₆H₂₉NO
Molar mass	371.515 g/mol 563.638 g/mol (citrate salt)
3D model (JSmol)	Interactive image
SMILES O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)CC)CCN(C)C
InChI InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-^Y Key:NKANXQFJJICGDU-QPLCGJKRSA-N^Y
(verify)